Syngene International has extended its long-term research collaboration with Bristol Myers Squibb (BMS) through 2035, reinforcing a partnership that spans more than two decades.
The renewed agreement expands the scope of collaboration across the entire drug development lifecycle, from early discovery to commercial support.
What the extended collaboration covers?
Under the new term, Syngene will continue to provide integrated, end-to-end services to BMS, including:
- Discovery and translational sciences
- Pharmaceutical development
- Manufacturing support
- Clinical trial enablement
- Data, digital, and IT services
The goal is simple: faster program progression, smoother handoffs, and long-term capacity planning.
A partnership built over 25+ years
The Syngene–BMS relationship began in 1998 and led to the creation of the Biocon Bristol Myers Squibb Research and Development Center (BBRC).
Key milestones:
- BBRC became Syngene’s first dedicated R&D centre
- Fully operational since 2009
- Now a core strategic R&D site for BMS
Today, the centre employs around 700 Syngene scientists working closely with BMS teams.
Scientific scope and therapeutic focus
BBRC supports a wide range of research and development activities, including:
- Target identification and validation
- Lead discovery and optimisation
- Molecular and cell biology
- Protein sciences and assay biology
- Pharmaceutical development
- Clinical biomarker research
These capabilities support BMS programmes across:
- Cardiovascular disease
- Fibrosis
- Immunology
- Oncology
Impact on BMS’ pipeline
Over the years, BBRC has helped advance multiple compounds from early discovery into first-in-human studies.
The collaboration has delivered:
- Shorter development timelines
- Lower overall R&D costs
- Strong support for patent generation
Why this extension matters?
The agreement signals a shift from project-based outsourcing to long-term strategic partnership.
For Syngene, it reinforces its position as:
- A global contract research and manufacturing partner
- A provider of integrated discovery-to-commercial solutions
- A long-term capacity and innovation partner for big pharma
For BMS, it ensures continuity, scale, and deep scientific integration to support future pipeline growth.
